Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Ann Thorac Surg. 2019 Aug 5;109(2):473–479. doi: 10.1016/j.athoracsur.2019.06.025

Table 2.

Association of HHI with odds of TAVR.

Model Proportion of patients receiving TAVR OR (CIs) p-value
HHI, Unadjusted
 High Competition 23.4% (3048/13037) 6.30 (3.68-10.8) <0.01
 Moderate Competition 11.0% (672/6136) 2.27 (1.21-4.26) <0.01
 Low Competition 10.8% (1840/16985) Ref Ref
HHI, Adjusted for patient-level factorsa
 High Competition 23.4% (3048/13037) 11.5 (6.09-21.6) <0.01
 Moderate Competition 11.0% (672/6136) 2.91 (1.51-5.60) <0.01
 Low Competition 10.8% (1840/16985) Ref Ref
HHI, Adjusted for patient-, and hospital-level factorsb
 High Competition 23.4% (3048/13037) 5.31 (2.10-13.4) <0.01
 Moderate Competition 11.0% (672/6136) 1.82 (0.79-4.22) 0.16
 Low Competition 10.8% (1840/16985) Ref Ref
a

Adjusted for: Year of procedure, sex, race, procedure status, admission from home paralysis, chronic lung disease, coagulation deficiency, congestive heart failure, deficiency anemias, depression, diabetes, electrolyte disorders, hypertension, hypothyroidism, neurologic disorders (not including paralysis), obesity, peripheral vascular disease, pulmonary circulatory disease, renal failure, valvular disease

b

Adjusted for patient-level factors, as well as for teaching hospital status, ownership status, bed size, and safety net status